145 related articles for article (PubMed ID: 31103265)
21. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
22. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
[TBL] [Abstract][Full Text] [Related]
23. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
24. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
[TBL] [Abstract][Full Text] [Related]
26. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
Qiu HB; Yang K; Yu HY; Liu M
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
[TBL] [Abstract][Full Text] [Related]
28. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
30. Lnc-NTF3-5 promotes osteogenic differentiation of maxillary sinus membrane stem cells via sponging miR-93-3p.
Peng W; Zhu SX; Wang J; Chen LL; Weng JQ; Chen SL
Clin Implant Dent Relat Res; 2018 Apr; 20(2):110-121. PubMed ID: 29106055
[TBL] [Abstract][Full Text] [Related]
31. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells.
Zhu M; Huang Y; Tang J; Shao S; Zhang L; Zhou Y; He S; Wang Y
Exp Hematol; 2020 Jan; 81():50-59. PubMed ID: 31899217
[TBL] [Abstract][Full Text] [Related]
32. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
35. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of XIST facilitates cell proliferation, invasion and suppresses cell apoptosis by reducing radio-sensitivity of glioma cells via miR-329-3p/CREB1 axis.
Wang YP; Li HQ; Chen JX; Kong FG; Mo ZH; Wang JZ; Huang KM; Li XN; Yan Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3190-3203. PubMed ID: 32271437
[TBL] [Abstract][Full Text] [Related]
37. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
38. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
39. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
[TBL] [Abstract][Full Text] [Related]
40. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
